Dopar
FDA Approves Dotarem, a New MRI Agent »
"The U.S. Food and Drug Administration today approved Dotarem (gadoterate meglumine) for use in magnetic resonance imaging (MRI) of the brain, spine and associated tissues of patients ages 2 years and older.
Dotarem is a gadolinium-based"...
Dopar
Please Note: This Brand Name drug is no longer available in the US.(Generic versions may still be available.)
CLINICAL PHARMACOLOGY
Evidence indicates that the symptoms of Parkinson's disease are related to depletion of striatal dopamine. Since dopamine apparently does not cross the blood-brain barrier, its administration is ineffective in the treatment of Parkinson's disease. However, levodopa, the levorotatory isomer of dihydroxy-phenylalanine (dopa) which is the metabolic precursor of dopamine, does cross the blood-brain barrier. Presumably it is converted into dopamine in the basal ganglia. This is generally thought to be the mechanism whereby oral levodopa acts in relieving the symptoms of Parkinson's disease.
The major urinary metabolites of levodopa in man appear to be dopamine and homovanillic acid (HVA). In 24-hour urine samples, HVA accounts for 13% to 42% of the ingested dose of levodopa.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Dopar Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.
Updated & New
